Table 2.
Calculated dose targeting in vivo EC50 as average drug concentration at steady state
| Treatment | Daily dose (mg/kg) | Dose (mg/kg) | Mw (kDa) | Daily dose (nM/kg) | Dose (nM/kg) | F or nPE | CL (L/h/kg) | EC50 (nM/L) | τ (h) |
|---|---|---|---|---|---|---|---|---|---|
| recFGF21 q6d | 0.191 | 0.032 | 19.3 | 9.9 | 1.6 | 1.09 | 3.3 | 0.136 | 4 |
| mFGF21 q.d. | 0.125 | 0.125 | 302 | 0.41 | 0.41 | 26 | 3.3 | 0.136 | 24 |
| recFc-FGF21 q.d. | 0.357 | 0.357 | 47.8 | 7.5 | 7.5 | 0.402 | 0.0047 | 26.6 | 24 |
| mFc-FGF21 q.d. | 0.368 | 0.368 | 512 | 0.72 | 0.72 | 0.858 | 0.0047 | 5.46 | 24 |
Mw, molecular weight; F, bioavailability; nPE, net production efficiency; CL, clearance; EC50, potency; τ, dosing interval.